Ero sivun ”Nifoksipaami” versioiden välillä

Nifoksipaami
	[[Tiedosto:\|275px\|]]
Tunnisteet
Muut nimet	3-hydroksidesmetyyliflunitratsepaami
CAS-numero	74723-10-7
PubChem CID	3058221
Ominaisuudet
Molekyylikaava	C15H10FN3O4
Moolimassa	315.256 g/mol
	Infobox OK

Uudempi muutos →

Poistettu sisältö Lisätty sisältö

VisuaalinenWikiteksti

Rivinsisäinen

Versio 15. helmikuuta 2017 kello 21.14

Nifoksipaami (DP 370) on bentsodiatsepiinijohdannainen, ja sitä muodostuu kehossa pieniä määriä flunitratsepaamin aineenvaihduntatuotteena. Sitä on myyty muuntohuumeena internetissä.^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]^[9]

Nifoksipaamilla on voimakas unta pidentävä ja ahdistusta poistava vaikutus, ja se on vähemmän toksinen lormetatsepaamiin ja flunitratsepaamiin verrattuna hiirillä.^[1]

↑ ^a ^b Klaus Posselt, Hans Heinrich Prof. Med. Wagener, Klaus Gruber: Patent EP 0158267 A2 - Pharmaceutical composition containing 5-(2-fluorophenyl)-1,3-dihydro-3-hydroxy-7-nitro- or 5-(2-fluorophenyl)-1,3-dihydro-3-hydroxy-1-methyl-7-nitro-2H-1,4-benzodiazepin-2-one and process for their preparation google.com. 16 October 1985. Viitattu 3 August 2015.
↑ Nifoxipam New Synthetic Drugs Database.
↑ "Flunitrazepam Metabolism by Cytochrome P450s 2C19 and 3A4" (April 2001). Drug Metabolism and Disposition 29 (4): 460–465. PMID 11259331.
↑ "Designer benzodiazepines: A new challenge" (June 2015). World Psychiatry 14 (2): 248. doi:10.1002/wps.20236. ISSN 1723-8617. PMID 26043347.
↑ Kevin Flemen: Drug Facts - Newer Unregulated Drugs August 2015. KFx. Viitattu 15 August 2015.
↑ Nifoxipam WEDINOS.
↑ "Identification of main human urinary metabolites of the designer nitrobenzodiazepines clonazolam, meclonazepam, and nifoxipam by nano-liquid chromatography-high-resolution mass spectrometry for drug testing purposes" (May 2016). Analytical and Bioanalytical Chemistry 408 (13): 3571-3591. doi:10.1007/s00216-016-9439-6. PMID 27071765.
↑ "Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays" (2016). Drug Testing and Analysis. doi:10.1002/dta.2003. PMID 27366870.
↑ "Metabolites replace the parent drug in the drug arena. The cases of fonazepam and nifoxipam" (2016). Forensic Toxicology. doi:10.1007/s11419-016-0338-5. ISSN 1860-8973.

[Kosselt_1985-1] Klaus Posselt, Hans Heinrich Prof. Med. Wagener, Klaus Gruber: Patent EP 0158267 A2 - Pharmaceutical composition containing 5-(2-fluorophenyl)-1,3-dihydro-3-hydroxy-7-nitro- or 5-(2-fluorophenyl)-1,3-dihydro-3-hydroxy-1-methyl-7-nitro-2H-1,4-benzodiazepin-2-one and process for their preparation google.com. 16 October 1985. Viitattu 3 August 2015.

[2] Nifoxipam New Synthetic Drugs Database.

[3] "Flunitrazepam Metabolism by Cytochrome P450s 2C19 and 3A4" (April 2001). Drug Metabolism and Disposition 29 (4): 460–465. PMID 11259331.

[MoosmannKing2015-4] "Designer benzodiazepines: A new challenge" (June 2015). World Psychiatry 14 (2): 248. doi:10.1002/wps.20236. ISSN 1723-8617. PMID 26043347.

[5] Kevin Flemen: Drug Facts - Newer Unregulated Drugs August 2015. KFx. Viitattu 15 August 2015.

[6] Nifoxipam WEDINOS.

[7] "Identification of main human urinary metabolites of the designer nitrobenzodiazepines clonazolam, meclonazepam, and nifoxipam by nano-liquid chromatography-high-resolution mass spectrometry for drug testing purposes" (May 2016). Analytical and Bioanalytical Chemistry 408 (13): 3571-3591. doi:10.1007/s00216-016-9439-6. PMID 27071765.

[8] "Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays" (2016). Drug Testing and Analysis. doi:10.1002/dta.2003. PMID 27366870.

[9] "Metabolites replace the parent drug in the drug arena. The cases of fonazepam and nifoxipam" (2016). Forensic Toxicology. doi:10.1007/s11419-016-0338-5. ISSN 1860-8973.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

Ero sivun ”Nifoksipaami” versioiden välillä

Versio 15. helmikuuta 2017 kello 21.14

Navigointivalikko

Haku